Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis

The objective of this study was to estimate the rate and significance of colonisation with vancomycin-resistant enterococci (VRE) among hospitalised children. The PubMed and EMBASE databases were systematically searched (last accessed on 29 May 2016) to identify studies evaluating VRE colonisation of the gastrointestinal tract of hospitalised children in non-outbreak periods. Of 945 non-duplicate citations, 19 studies enrolling 20 234 children were included. The overall and paediatric intensive care unit (PICU) rate of VRE colonisation were both 5% [95% confidence interval (CI) 3-8% overall and 95% CI 2-9% in the PICU] but was 23% in haematology/oncology units (95% CI 18-29%). Studies that were exclusively performed in haematology/oncology units reported significantly higher rates compared with all other studies in the univariate and multivariate analyses (P = 0.001). Previous vancomycin [risk ratio (RR) = 4.34, 95% CI 2.77-6.82] or ceftazidime (RR = 4.15, 95% CI 2.69-6.40) use was a risk factor for VRE colonisation. Importantly, VRE colonisation increased the risk of subsequent VRE infection (RR = 8.75, 95% CI 3.19-23.97). In conclusion, a high rate of VRE colonisation was found among hospitalised children in institutions that performed targeted screening. Importantly, colonised children were almost 9 times more likely to develop subsequent VRE infection. Judicious use of specific antibiotics along with intensification of infection control measures should be considered in high-prevalence institutions. Also, the high incidence of VRE colonisation among children with haematological/oncological diseases identifies a high-risk population.

Is it worth screening for vancomycin-resistant Enterococcus faecium colonization?: Financial burden of screening in a developing country

BACKGROUND

The screening of critically ill patients at high risk of vancomycin resistant enterococci (VRE) colonization, to detect and isolate colonized patients, is recommended to prevent and control the transmission of VRE. Screening asymptomatic carriers brings financial burden for institutions. In this study, we performed risk analysis for VRE colonization and determined the financial burden of screening in a middle-income country, Turkey.

METHODS

We retrospectively analyzed the VRE surveillance data from a pediatric hospital between 2010 and 2014. A case-control study was conducted to identify the risk factors of colonization. Total cost of VRE screening and additional costs for a VRE colonized patient (including active surveillance cultures and contact isolation) were calculated.

RESULTS

During the 4-year period, 6,372 patients were screened for perirectal VRE colonization. The rate of culture-positive specimens among all patients screened was 239 (3.75%). The rate of VRE infection was 0.04% (n = 3) among all patients screened. Length of hospital stay, malignancy, and being transferred from another institution were independently associated risk factors for colonization. Annual estimated costs for the laboratory were projected as $19,074 (76,295/4) for all patients screened. Cost of contact isolation for each patient colonized in a ward and an intensive care unit was $270 and $718, respectively.

CONCLUSIONS

In developing countries, institutions should identify their own high-risk patients; screening priorities should be based on prevalence of infection and hospital financial resources.

Optimizing the Use of Antibacterial Agents in the Neonatal Period

Antibiotics are invaluable in the management of neonatal infections. However, overuse or misuse of antibiotics in neonates has been associated with adverse outcomes, including increased risk for future infection, necrotizing enterocolitis, and mortality. Strategies to optimize the use of antibiotics in the neonatal intensive care unit include practicing effective infection prevention, improving the diagnostic evaluation and empiric therapy for suspected infections, timely adjustment of therapy as additional information becomes available, and treating proven infections with an effective, narrow-spectrum agent for the minimum effective duration. Antibiotic stewardship programs provide support for these strategies but require the participation and input of neonatologists as stakeholders to be most effective.

Controlling the spread of vancomycin-resistant enterococci. Is active screening worthwhile?

Vancomycin-resistant enterococci (VRE) are significant causes of healthcare-acquired infections. Active screening, i.e. the use of rectal swabs or faeces to detect carriage in at-risk patients, has been described as contributing to prevention by identifying previously unrecognized cases. The aim of this review was to determine the impact of screening for VRE on prevention and control, its cost-effectiveness and recent approaches to laboratory detection. A review of published studies in English from 2000 was undertaken. Whereas various guidelines were accessed and reviewed, the emphasis was on original reports and studies. It was determined that the patient groups who may need screening are those admitted to critical care units, haematology/oncology and transplant wards, patients on chronic dialysis and patients admitted to acute hospitals from long-stay units. Active screening is associated with reduced VRE colonization and infection and cost savings in some studies, even if these fall short of randomized trials. Selective media increase sensitivity and reduce the time to detection but the role of molecular methods remains to be determined. In conclusion, active screening contributes to VRE prevention probably by heightening awareness of control measures, including isolation. However, further studies are required to: better define high-risk groups that warrant screening; quantify the clinical and economic benefit; and determine the optimal laboratory methods in a range of different patient populations.

Sources of systematic errors in the epidemiology of vancomycin-resistant enterococci

PURPOSE

The rates of vancomycin resistance among enterococci (VRE) have been increasing worldwide. However, reports on vancomycin-resistant enterococci (VRE) are easily biased and meta-data reporting is insufficient. Additionally, no standardised protocol for VRE testing currently exists. The aim of our study was to investigate, for the first time, the impact of introduced bias in VRE reports. We also analysed the sensitivity of our in-house screening test for VRE, namely, a broth-enriched PCR assay.

METHODS

Retrospective review of microbial and clinical data on all patients tested for VRE who had been admitted to a large university hospital over a 5-year period and an analysis of the possible impact of introduced bias. Our screening test was also evaluated using clinical isolates.

RESULTS

A total of 27,636 screening tests were carried out over the 5-year study period, of which 2,459 were VRE-positive. The number of screening tests increased dramatically over the study period, with 1,053 tests carried out on 435 patients in 2006 and 9,444 tests carried out on 5,104 patients in 2010. VRE prevalence was 8.1 % over the 5-year period. The introduction of measurement bias caused a clear overestimation of absolute VRE numbers. The sensitivity of our screening test was 95.5 % with a positive predictive value of 39 %.

CONCLUSION

Biased reports lead to the implementation of high-cost containment measures that may be both unnecessary and detrimental to the patient. Our data show that systematic errors in VRE reports caused a clear overestimation of absolute VRE numbers, thereby indicating an outbreak situation even though the actual prevalence of VRE was decreasing. We suggest that reports of VRE must take measurement and analysis biases into account, otherwise any conclusion drawn is unreliable and inconclusive.

Trends in antimicrobial resistance in intensive care units in the United States

PURPOSE OF REVIEW

Antimicrobial resistance and a paucity of new antimicrobial agents are ongoing challenges. This review focuses on the major epidemiologic trends and novel treatments, when available, for methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus, Clostridium difficile, and multidrug-resistant Gram-negative bacilli in the United States during 2010-2011.

RECENT FINDINGS

MRSA bloodstream infection rates have declined, primarily due to interventions aimed at decreasing vascular catheter infections. The proportion of MRSA due to the community-associated strain USA300 continues to increase. Recent studies of active surveillance and contact isolation for MRSA prevention provide conflicting views of efficacy. Two novel treatments for recurrent C. difficile infection, monoclonal antibodies and fidaxomicin, show promising results. Antimicrobial resistance among Gram-negative bacilli has become widespread; extended-spectrum beta-lactamases are now commonly found among Escherichia coli causing community-acquired infections in the United States. Klebsiella pneumoniae carbapenemases have spread beyond the northeast, and the New Delhi metallo-beta-lactamase has been reported in multiple countries within a few years of its discovery.

SUMMARY

Antimicrobial resistance, particularly among Gram-negative bacilli, continues to increase at a rapid rate. Given the frequent transfer of patients between outpatient and acute care settings, as well as between different geographic regions, coordinated infection control interventions are warranted.

The past, present, and future of healthcare‐associated infection prevention in pediatrics: multidrug‐resistant organisms

Multidrug resistant organisms (MDROs) and healthcare‐associated infections (HAIs) are associated with increased lengths of hospital stay, increased costs, and increased mortality. We explore the scope of MDRO HAIs in children, current MDRO HAI prevention practices and data to support these practices, and we propose research topics targeting MDRO HAI prevention in children.

Prevention of healthcare-associated infections in children: new strategies and success stories

PURPOSE OF REVIEW

Attention to patient safety has made hospital infection prevention and control strategies a subject of increasing focus from healthcare personnel, patients and families, accrediting organizations, and government. This review highlights recent literature and new successes in the prevention of healthcare-associated infections in children.

RECENT FINDINGS

Emerging evidence about risk factors for various healthcare-associated infections in children will help target available adjunctive preventive interventions. Multicenter pediatric collaborative efforts to emphasize best practices have resulted in decreases in infection rates, particularly for central line-associated bloodstream infections. A low prevalence of colonization or infection with multidrug-resistant organisms in hospitalized children, combined with a lack of compelling evidence of effectiveness for active surveillance and decolonization, have made decisions about routine screening challenging.

SUMMARY

A renewed interest in infection prevention by multiple stakeholders has energized our field and contributed to impressive successes in reducing rates of healthcare-associated infections. Nevertheless, important knowledge gaps remain and an emphasis on funding of high-quality, rigorous studies to answer unresolved questions will be critical to our efforts to further prevent infections for hospitalized children.